# Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

> **NCT00083148** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00083148
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2005-03
- **Final completion:** 2006-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2011-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083148, "Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00083148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*